Integer Holdings Corp. Faces Shareholder Claims Over Alleged Misstatements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: Globenewswire
- Shareholder Claims Investigation: Grabar Law Office is investigating claims on behalf of Integer Holdings Corp. shareholders, alleging that certain executives breached their fiduciary duties, potentially leading to corporate reforms and fund recovery for shareholders.
- Allegations of Misstatements: A recently filed securities fraud class action claims that Integer materially misrepresented its competitive position in the EP device market, undermining financial transparency and investor trust.
- Sales Decline Risks: Despite claims of strong visibility into customer demand, the company is reportedly experiencing a sustained decline in sales of its EP devices, which could significantly lower future revenue expectations.
- Potential Legal Consequences: Shareholders who purchased Integer stock before July 25, 2024, and still hold it may face legal repercussions, impacting corporate governance and shareholder rights.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ITGR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 85.900
Low
75.00
Averages
93.38
High
140.00
Current: 85.900
Low
75.00
Averages
93.38
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Integer Holdings Faces Class Action Securities Lawsuit
- Lawsuit Background: Levi & Korsinsky LLP has notified investors that Integer Holdings Corporation (NYSE: ITGR) is facing a class action securities lawsuit for alleged fraud between July 25, 2024, and October 22, 2025, potentially leading to significant investor losses.
- Allegations: The lawsuit claims that Integer materially overstated its competitive position in the electrophysiology manufacturing market and concealed deteriorating sales of its electrophysiology devices, misleading investors about the company's prospects.
- Legal Implications: Investors must apply by February 9, 2026, to be appointed as lead plaintiff to share in any recovery, with no out-of-pocket costs required, thereby lowering the barrier for investor participation.
- Law Firm Expertise: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex cases.
Continue Reading
Integer Holdings Corporation Class Action Reminder
- Sales Guidance Cut: On October 23, 2025, Integer lowered its full-year sales guidance to between $1.840 billion and $1.854 billion, below expectations, forecasting net sales growth of -2% to 2% for 2026, which significantly undermines investor confidence.
- Decline in New Product Sales: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026 due to slower market adoption, further impacting overall performance.
- Stock Price Plummet: Following the sales guidance cut, Integer's stock price fell by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
- Class Action Initiated: Investors who purchased Integer stock between July 25, 2024, and October 22, 2025, and suffered losses can file to become lead plaintiffs in a class action lawsuit by February 9, 2026, alleging significant misstatements regarding sales and market prospects.
Continue Reading